BFNH Company Profile and Key Details

Average 10-day trading volume of 22.63 thousand shares is significantly above the 3-month average of 9.97 thousand, indicating heightened recent market interest.

BioForce Nanosciences Holdings, Inc. (OTC:BFNH) closed at $8.20 USD, gaining $1.13 (15.98%) from the previous close of $7.07. The stock is currently mid-range between its 52-week high and low $0.18 and $10.15. With a market capitalization of about $275.10 million, BioForce Nanosciences Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.40). Key stats such as the average daily volume over the past year has been around 7.98 thousand shares, trading with heavier-than-usual volume. Headquartered in Virginia Beach, VA, BioForce Nanosciences Holdings, Inc. operates in the Consumer Defensive sector and the Packaged Foods industry. Led by CEO Richard James Kaiser, the company employs approximately 3 people and listed since May 01, 2007. BioForce Nanosciences Holdings, Inc. (BFNH) specializes in providing natural vitamins, minerals, and a variety of other nutritional supplements, along with powders and beverages, intended for individuals across all age demographics.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

BioForce Nanosciences Holdings, Inc. trades at a P/E ratio of -2600.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 113.6 reflecting a rich premium to book value. The P/FCF stands at -6206.74, also below market averages. Compared to sector medians, BioForce Nanosciences Holdings, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that BioForce Nanosciences Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows BioForce Nanosciences Holdings, Inc. trading at a premium to the broader market with a P/E of -2600.0.